Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 3.92M.
Subavaliada
O PE mais recente da empresa é -9.18, em uma faixa percentil baixa de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 229.52M ações, uma redução de 0.34% em relação ao trimestre anterior.
Mantido por The Vanguard
O Super Investidor The Vanguard possui 9.07M ações desta empresa.
Alta Atividade de Mercado
A empresa tem maior interesse dos investidores, com uma taxa de giro de 20 dias de 5.55.